Fluticasone furoate vilanterol
Pro Research Analysisby 
Searched over 200M research papers
Fluticasone Furoate and Vilanterol: Efficacy and Safety in COPD and Asthma Management
Introduction to Fluticasone Furoate and Vilanterol
Fluticasone furoate and vilanterol are combined in a once-daily inhaled medication used to manage chronic obstructive pulmonary disease (COPD) and asthma. Fluticasone furoate is an inhaled corticosteroid (ICS), while vilanterol is a long-acting β2-agonist (LABA). This combination aims to reduce exacerbations and improve lung function in patients with these chronic respiratory conditions.
Efficacy in COPD Management
Reduction in Exacerbations
Several studies have demonstrated that the combination of fluticasone furoate and vilanterol significantly reduces the rate of moderate and severe exacerbations in COPD patients compared to vilanterol alone. In two replicate double-blind, parallel-group, randomized controlled trials, the combination therapy showed a significant reduction in exacerbation rates across all doses of fluticasone furoate when compared to vilanterol alone . Another study confirmed these findings, showing that the combination therapy reduced exacerbations by 8.4% compared to usual care in a real-world clinical practice setting .
Improvement in Lung Function
The combination of fluticasone furoate and vilanterol has also been shown to improve lung function in COPD patients. A randomized trial demonstrated significant improvements in both weighted mean forced expiratory volume in 1 second (FEV1) and trough FEV1 with the combination therapy compared to placebo and individual components . Another study found that the combination therapy provided rapid and sustained bronchodilation over 24 weeks .
Blood Eosinophil Counts as a Biomarker
Blood eosinophil counts have been identified as a potential biomarker for predicting the response to inhaled corticosteroids in COPD patients. Patients with higher eosinophil counts (≥2%) experienced a greater reduction in exacerbation rates when treated with fluticasone furoate and vilanterol compared to those with lower eosinophil counts .
Efficacy in Asthma Management
Improvement in Asthma Control
In asthma management, the combination of fluticasone furoate and vilanterol has been shown to improve asthma control significantly. A systematic review and meta-analysis found that the combination therapy was associated with significant increases in trough FEV1 and peak expiratory flow rates compared to fluticasone furoate monotherapy and other ICS-LABA formulations . Additionally, an open-label, randomized controlled trial demonstrated that patients initiating treatment with the combination therapy had higher odds of achieving better asthma control compared to those on optimized usual care .
Safety and Tolerability
The safety profile of fluticasone furoate and vilanterol has been extensively studied. In a 52-week randomized trial, the combination therapy was well tolerated in patients aged 12 years and older with asthma, with no significant clinical concerns identified . Similarly, in COPD patients, the combination therapy did not show an excess risk of serious adverse events, including pneumonia, compared to usual care .
Conclusion
The combination of fluticasone furoate and vilanterol is effective in reducing exacerbations and improving lung function in COPD patients, with blood eosinophil counts serving as a useful biomarker for predicting response. In asthma management, the combination therapy improves asthma control and is well tolerated. These findings support the use of fluticasone furoate and vilanterol as a valuable treatment option for patients with chronic respiratory conditions.
Sources and full results
Most relevant research papers on this topic
Once-daily fluticasone furoate and vilanterol for adolescents and adults with symptomatic asthma: A systematic review with meta-analysis.
Fluticasone furoate-vilanterol combination improves trough FEV1 and reduces severe asthma exacerbations, but differences may not be clinically significant.
DOI